Tyrosine kinase inhibitors

Aus coViki
Wechseln zu: Navigation, Suche
PHA conventional pharmacology

mixed retargeted oncopharmaceuticals

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
32348877 ä. Chemical evolution for taming the ?pathogenic kinase? PAK1

32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19
32599278 2020. Imatinib for COVID-19: A case report.

BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.

32552307 2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.

akt PKB
32519895 2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?

Abelson tyrosine kinase
32399097 2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.
32395220 2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.

p38 mapk
32422320 2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.

Meine Werkzeuge